US67080N1019 - Common Stock
NUVATION BIO INC
NYSE:NUVB (9/27/2023, 7:04:01 PM)
After market: 1.44 +0.04 (+2.86%)1.4
+0.01 (+0.72%)
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2020-07-01. The firm is focused on developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company’s clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. The company has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its drug-drug conjugate (DDC) platform is a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
NUVATION BIO INC
357 Tehama Street, Floor 3
San Francisco CALIFORNIA 94103
P: 14157543517.0
CEO: David Hung
Employees: 54
Website: https://www.nuvationbio.com/
Nuvation Bio press release (NUVB): Q1 GAAP EPS of -$0.10.Strong balance sheet with cash, cash equivalents and marketable securities of $646.6 million as of March 31, 2023
Here you can normally see the latest stock twits on NUVB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: